Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LAB Research Q3 revenues up 3.1%
LAB Research has posted a net loss of C$2.64m for the third quarter 2010, or C$0.05 loss per diluted share, compared to net loss of C$1.7m, or C$0.09
LAB Research has posted a net loss of C$2.64m for the third quarter 2010, or C$0.05 loss per diluted share, compared to net loss of C$1.7m, or C$0.09
Nautilus Neurosciences and Tribute Pharma claimed that a new, water-soluble, buffered diclofenac potassium powder – Cambia is the only prescription non – steroidal anti-inflammatory drug (NSAID) available for
The co-promotion agreement enables Quintiles and Kadrige to develop Web-Call centers, which allow medical sales representatives to train or call healthcare professionals on a full-time basis. Kadrige and
Jiangbo Pharma has posted a net income of $10.57m for the first quarter 2010, or $0.29 per diluted share, compared to net income of $1.97m, or $1.68 loss
Ono Pharma’s Phase 2 comparison study is designed to demonstrate efficacy and safety of subcutaneous methylnaltrexone in Japanese subjects. The drug, designated ONO-3849 in Japan, is being evaluated
Impax’s generic division Global Pharmaceuticals is expected to launch the product. Impax claimed that the FDA awarded the company 180 days of generic drug exclusivity as it was
As per the terms of the agreement, Eisai is expected to have non-exclusive access to Forma’s Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to
As per the terms of the agreement, Zydus will market ABI’s dietary supplement Maxisal in India and Nepal. Maxisal enhances salivary function, promotes oral comfort and helps relieve
Amylin said that the study will be conducted by researchers at The University of Texas (UT) Southwestern Medical Cente. Prior studies at UT Southwestern conducted in animal models
Aoxing Pharma has posted a net loss of $653,939 for the first quarter 2010, or $0.01 loss per diluted share, compared to $2.29m, or $0.05 loss per diluted